 Patients will be randomized in a 1:1 ratio to 2 treatment arms durvalumab or SOC therapy. The Co-primary objectives of this study are to assess the efficacy of durvalumab compared to SoC in terms of PFS Progression Free Survival and OS Overall Survival in patients with NSCLC 